Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | FLT3 | P36888 | 1/20 | 0.82 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.82 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.82 |
| ▸ | KIT | P10721 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17325093 | 0.97 | ABL1 (0.78) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL18775253 | 0.92 | ABL1 (0.68) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29514988 | 0.90 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29387193 | 0.90 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL3424528 | 0.90 | ABL1 (1.00) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| SCHEMBL18775236 | 0.90 | ABL1 (0.66) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL14953130 | 0.90 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL29515011 | 0.90 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL30456095 | 0.90 | ABL1 (0.99) | ABL1FGFR1CYP2C9PDGFRACYP2C19 | |
| Olverembatinib SCHEMBL14953403 | 0.88 | ABL1 (0.94) | ABL1FGFR1CYP2C9PDGFRACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | claimed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | claimed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | claimed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015186137-A1 | 1H-1,8- NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | ABL1 1/4885FGFR1 37/4885CYP2C9 1705/4885 |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, ABL2 | ABL1 1/4885FGFR1 40/4885CYP2C9 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.